Tyrosine kinase inhibitors. 14. Structure-activity relationships for methyl-amino-substituted derivatives of 4-[3-bromophenyl)amino]-6- (methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors

Journal of Medicinal Chemistry

Volumn 41, Issue 5, 1998, Pages 742-751

  Rewcastle, Gordon W ^a   Murray, Donna K ^a   Elliott, William L ^a   Fry, David W ^a   Howard, Curtis T ^a   Nelson, James M ^a   Roberts, Billy J ^a   Vincent, Patrick W ^a   Hollis Showalter, H D ^a   Thomas Winters, R ^a   Denny, William A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CANCER GRAFT; CANCER INHIBITION; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, NUDE; MOLECULAR STRUCTURE; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 15444361739     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970641d     Document Type: Article

References (37)

1. Bridges, A. J. The epidermal growth factor receptor family of tyrosine kinases and cancer: can an atypical exemplar be a sound therapeutic target? Curr. Med. Chem. 1996, 3, 167-194.
2. Fry, D. W. Recent advances in tyrosine kinase inhibitors. Annu. Rep. Med. Chem. 1996, 37, 151-160.
3. Rusch, V.; Mendelsohn, J.; Dmitrovsky, E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev. 1996, 7, 133-141.
4. Yamada, M.; Ikeuchi, T.; Hatanaka, H. The neurotrophic action and signaling of epidermal growth factor. Prog. Neurobiol. 1997, 51, 19-37.
5. Lupu, R.; Lippmann, M. E. The role of erbB2 signal transduction pathways in human breast cancer. Breast Cancer Res. Treat. 1993, 27, 83-93.
6. Hickey, K; Grehan, D.; Reid, I. M.; O'Briain, S.; Walsh, T. N.; Hennessy, T. P. J. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 1994, 74, 1693-1698.
7. Delarue, J. C.; Terrier, P.; Terrier-Lacombe, M. J.; Mouriesse, H.; Grotteland, M.; May-Levin, F. Combined overexpression of c-erbB-2 protein and epidermal growth factor receptor (EGF.-R) could be predictive of early and long-term outcome in human breast cancer: a pilot study. Bull. Cancer 1994, 81, 1067-1077.
8. Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambrose, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265, 1093-1095.
9. Ward, W. H. J.; Cook, P. N.; Slater, A. M.; Davies, D. H.; Holdgate, G. A.; Green, L. R. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 1994, 48, 659-666.
10. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H.; Cody, D. R.; McMichael, A.; Fry, D. W. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenyl-methyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3482-3487.
11. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; Mc-Michael, A.; Showalter, H. D. H.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 267-276.
12. Wakeling, A. E.; Barker, A. J.; Davies, D. H.; Brown, D. S.; Green, L. R.; Cartlidge, S. A; Woodburn, J. R. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anili-noquinazolines. Breast Cancer Res. Treat. 1996, 38, 67-73.
13. Woodburn, A. J.; Barker, A. J.; Gibson, K. H.; Ashton, S. E.; Wakeling, A. E.; Curry, B. J.; Scarlett, L.; Henthorn, L. R. ZD 1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical trial development. Proc. Am. Assoc. Cancer Res. 1997, 38, 633 (Abstract 4251).
14. Iwata, K.; Miller, P. E.; Barbacci, E. G.; Arnold, L.; Doty, J.; DiOrio, C. I.; Pustilnik, L. R.; Reynolds, M.; Theleman, A.; Sloan, D.; Moyer, J. D. CP-358,774: a selective EGFR kinase inhibitor with potent antiproliferative activity against HN5 head and neck tumor cells. Proc. Am. Assoc. Cancer Res. 1997, 38, 633 (Abstract 4248).
15. Rewcastle, G. W.; Palmer, B. D.; Thompson, A. M.; Bridges, A. J.; Cody, D. R.; Zhou, H.; Fry, D. W.; McMichael, A.; Denny, W. A. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)-amino]pyrido[d]pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 1823-1835.
16. Fry, D. W.; Nelson, J. M.; Slintak, V.; Keller, P. R.; Rewcastle, G. W.; Denny, W. A.; Zhou, H.; Bridges, A. J. Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochem. Pharmacol. 1997, 54, 877-887.
17. erbB4. Nature 1993, 366, 473-475.
18. Sliwkowski, M. X.; Schaefer, G.; Akita, R. W.; Lofgren, J. A.; Fitzpatrick, V. D.; Nuijens, A.; Fendly, B. M.; Cerione, R. A; Vandlen, R. L.; Carraway, K. L. Coexpression of erbB2 and erbB3 reconstitutes a high-affinity receptor for heregulin. J. Biol. Chem. 1994, 269, 14661-14665.
19. Palmer, B. D.; Trumpp-Kallmeyer, S.; Fry, D. W.; Nelson, J. M.; Showalter, H. D. H.; Denny, W. A. Tyrosine Kinase Inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding. J. Med. Chem. 1997, 40, 1519-1529.
20. Thompson, A. M.; Murray, D. K.; Elliott, W. L.; Fry, D. W.; Nelson, J. A.; Showalter, H. D. H.; Roberts, B. J.; Vincent, P. W.; Denny, W. A. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1997, 40, 3915-3925.
21. Rewcastle, G. W.; Denny, W. A.; Winters, R. T.; Colbry, N. L.; Showalter, H. D. H. Synthesis of 6-substituted pyrido[3,4-d]-pyrimidin-4(3H)-ones via directed lithiation of 2-substituted 5-aminopyridine derivatives. J. Chem. Soc., Perkin Trans. 1 1996, 2221-2226.
22. Kohn, K. W.; Orr, A.; O'Connor, P. M. Synthesis and DNA-sequence selectivity of a series of mono- and difunctional 9-aminoacridine nitrogen mustards. J. Med. Chem. 1994, 37, 67-72.
23. Thompson, A. M.; Bridges, A. J.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)-and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines; a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3780-3788.
24. Traxler, P. M.; Furet, P.; Mett, H.; Buchdunger, E.; Meyer, T.; Lydon, N. 4-(Phenylamino)pyrrolopyrimidines: potent and selective ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 1996, 39, 2285-2292.
25. (25) Rewcastle, G. W.; Bridges, A. J.; Fry, D. W.; Rubin, J. R.; Denny, W. A. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-anpyrimidines designed as inhibitors of the epidermal growth factor receptor. J. Med. Chem. 1997, 40, 1820-1826.
26. Jones, J. A.; Howard, C. T.; Roberts, B. J.; Elliott, W. L. In vivo establishment and characterization of a murine fibroblast cell line transfected with the human EGF receptor. Proc. Am. Assoc. Cancer Res. 1994, 35, 84 (Abstract 499).
27. Böhme, H.; Osmers, K. d-Halo amines. XLII. Reactions in the imidazolidine and oxazolidine series. Chem. Ber. 1972, 105, 2237-2245.
28. Tkaczynski, T. Synthesis of ethylene amines. VIII. Condensation of N-alkyl-N'-acetylethylenediamines with ethylene oxide and cyclization of the reaction products to N-alkylpiperazines. Acta Polon. Pharm. 1966, 23, 15-18; Chem. Abstr. 1966, 64, 17594d.
29. Tkaczynski, T. Synthesis of ethylene amines. VIII. Condensation of N-alkyl-N'-acetylethylenediamines with ethylene oxide and cyclization of the reaction products to N-alkylpiperazines. Acta Polon. Pharm. 1966, 23, 15-18; Chem. Abstr. 1966, 64, 17594d.
30. Preston, R. K.; Peck, R. M.; Breuninger, E. R.; Miller, A. J.; Creech, H. J. Further investigations of heterocyclic alkylating agents. J. Med. Chem. 1964, 7, 471-480.
31. Gilman, H.; Sherman, C. S.; Price, C. C.; Elderfield, R. C.; Maynard, J. T.; Reitsema, R. H.; Tolman, L.; Massie, S. P.; Marshall, F. J.; Goldman, L. Synthesis of 1-diethylamino-2,3-epoxypropane, 3-diethylamino-2-hydroxypropylamine, and 4-diethylamino-3-hydroxybutylamine. J. Am. Chem. Soc. 1946, 68, 1291-1293.
32. Gill, G. N.; Weber, W. Purification of functionally active epidermal growth factor receptor protein using a competitive antagonist monoclonal antibody and competitive elution with epidermal growth factor. Methods Enzymol. 1987, 146, 82-88.
33. Schabel, F. M., Jr.; Griswold, D. P., Jr.; Laster, W. R., Jr.; Corbett, T. H.; Lloyd, H. H. Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol. Ther. 1977, 1, 411-435.
34. Leopold, W. R.; Nelson, J. M.; Plowman, J.; Jackson, R. C. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. Cancer Res. 1985, 45, 5532-5539.
35. Elliott, W. L.; Howard, C. T.; Dykes, D. J.; Leopold, W. R. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice. Cancer Res. 1989, 49, 5586-5590.
36. Elliott, W. L.; Roberts, B. J.; Howard, C. T.; Leopold, W. R. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato-(2-)](2-methyl-1,4-butanediamine-N, N') platinum (CI-973,NK121) in combination with standard agents against murine tumors in vivo. Cancer Res. 1994, 54, 4412-4418.
37. Fry, D. W.; Kraker, A. J.; Connors, R. C.; Elliott, W. L.; Nelson, J. M.; Showalter, H. D. H.; Leopold, W. R. Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity. Anti-Cancer Drug Des. 1994, 5, 331-351.